ArticleScientific reports2025
Glaucoma screening in Kazakhstan.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluation of a National Breast Cancer Screening Program in a Middle-Income Country: The Case of Kazakhstan.International journal of environmental research and public health · 2026Article
- Antimicrobial Resistance and the Blood-Brain Barrier: Complex Interactions and Implications for Neurological Health.Molecular neurobiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to conduct a comprehensive analysis of the national glaucoma screening program in Kazakhstan from 2000 to 2022. A thorough search was conducted to identify policy documents regulating the provision of glaucoma screening from its inception to the present day. Official data on reimbursement for tonometry, glaucoma incidence, and the population aged ≥ 50 years were retrieved. Forecast modeling was utilized to project disease incidences up to 2030. The current program largely inherits the framework of the Soviet glaucoma screening, with tonometry serving as the primary screening tool. The budget allocated for glaucoma screening is not specified in official documents, as glaucoma screening is integrated into the routine activities of healthcare facilities. The highest costs are incurred when Maklakov tonometry is applied alone, reaching 7,557,679,411 Kazakhstani Tenge in 2023. The incidence of glaucoma increased from 59.1 per 100,000 in 2000 to 135.5 in 2022, reflecting the aging population. Disparities in incidence rates were observed between residents of urban and rural areas, as well as among residents of different provinces. It is anticipated that the incidence of glaucoma will continue to rise, reaching 154.5 per 100,000 in 2030. There is a need to initiate a discussion on potential amendments to the existing screening program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.